Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

73 trials with published results (40%)

Research Maturity

155 completed trials (84% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

3.8%

7 terminated out of 184 trials

Success Rate

95.7%

+9.2% vs benchmark

Late-Stage Pipeline

40%

73 trials in Phase 3/4

Results Transparency

47%

73 of 155 completed with results

Key Signals

73 with results96% success

Data Visualizations

Phase Distribution

169Total
Not Applicable (22)
Early P 1 (2)
P 1 (31)
P 2 (41)
P 3 (52)
P 4 (21)

Trial Status

Completed155
Unknown13
Terminated7
Recruiting4
Withdrawn4
Active Not Recruiting1

Trial Success Rate

95.7%

Benchmark: 86.5%

Based on 155 completed trials

Clinical Trials (184)

Showing 20 of 20 trials
NCT07144345Phase 3RecruitingPrimary

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

NCT07144852Phase 3RecruitingPrimary

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

NCT06888362Phase 1CompletedPrimary

Trial to Investigate GZ21T in Healthy Volunteers

NCT06778434Phase 2RecruitingPrimary

The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans

NCT06027619Phase 2CompletedPrimary

Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses

NCT05699603Phase 2Active Not RecruitingPrimary

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

NCT06319794Phase 2CompletedPrimary

Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis

NCT00472459Phase 3CompletedPrimary

Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer

NCT01820260Phase 1CompletedPrimary

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

NCT02549352Phase 3CompletedPrimary

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

NCT03115476Phase 3TerminatedPrimary

A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp

NCT02549339Phase 3CompletedPrimary

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

NCT02361216Phase 3CompletedPrimary

Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest

NCT02547233Phase 3CompletedPrimary

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

NCT01541553Phase 3CompletedPrimary

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

NCT02547363Phase 3CompletedPrimary

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

NCT01998984Phase 2CompletedPrimary

Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

NCT02305888Phase 2CompletedPrimary

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

NCT01600014Phase 3CompletedPrimary

Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

NCT01449513Phase 1CompletedPrimary

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy

Scroll to load more

Research Network

Activity Timeline